Zenocutuzumab, a HER2×HER3 Biclonics® Antibody that can Overcome HER3 Mediated NRG1 Signaling in Tumor Cells by Docking on HER2

Time: 12:30 pm
day: Day Two

Details:

• Understanding the status of HER2 and NRG1 fusions
• Understanding how Merus are overcoming resistance & leveraging inhibition of signaling
• Uncovering the latest data and future directions